$NVS

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

American Kidney Fund launches "Kidneys Count" campaign March 1, 2026, promoting early detection and prevention of kidney disease affecting 1 in 7 American adults.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.

Novartis maintains growth despite patent challenges, backed by a strong product portfolio of 15 billion-dollar brands and nearly 30 years of consecutive dividend increases.

Novo Nordisk shares fell 16% after CagriSema obesity drug trial underperformed rival Eli Lilly's tirzepatide. Deutsche Bank downgraded the stock amid competitive concerns.

PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.

Turner Syndrome treatment market projected to double to $3.67B by 2033, driven by diagnostic innovation, increased awareness, and improved access to therapies globally.

Novartis's kidney drug Vanrafia shows sustained efficacy in slowing kidney function decline, supporting its path to full regulatory approval in 2026 for IgA nephropathy treatment.